CA2433386A1 - Compositions and methods involving an essential staphylococcus aureus gene and its encoded protein staau_r9 - Google Patents

Compositions and methods involving an essential staphylococcus aureus gene and its encoded protein staau_r9 Download PDF

Info

Publication number
CA2433386A1
CA2433386A1 CA002433386A CA2433386A CA2433386A1 CA 2433386 A1 CA2433386 A1 CA 2433386A1 CA 002433386 A CA002433386 A CA 002433386A CA 2433386 A CA2433386 A CA 2433386A CA 2433386 A1 CA2433386 A1 CA 2433386A1
Authority
CA
Canada
Prior art keywords
staphylococcus aureus
compositions
encoded protein
methods involving
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002433386A
Other languages
French (fr)
Other versions
CA2433386C (en
Inventor
Jerry Pelletier
Philippe Gros
Michael Dubow
Dominique Bergeron
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Targanta Therapeutics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2433386A1 publication Critical patent/CA2433386A1/en
Application granted granted Critical
Publication of CA2433386C publication Critical patent/CA2433386C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Abstract

The invention relates to bacterial genes and proteins that are implicated in the process of DNA replication and also to bacteriophage genes and their protein products that interact with bacterial proteins involved in DNA
replication.
The invention also relates to antibacterial agents, compositions and methods for inhibiting bacterial growth, and more particularly for inhibiting primase DnaG
activity in Staphylococcus aureus. In addition, the invention relates to screening assays to identify novel antibacterial agents binding to Staphylococcus aureus DnaG primase.
CA002433386A 2000-12-19 2001-12-19 Compositions and methods involving an essential staphylococcus aureus gene and its encoded protein staau_r9 Expired - Fee Related CA2433386C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25634900P 2000-12-19 2000-12-19
US60/256,349 2000-12-19
PCT/CA2001/001848 WO2002050545A2 (en) 2000-12-19 2001-12-19 Compositions and methods involving staphylococcus aureus protein staau-r9

Publications (2)

Publication Number Publication Date
CA2433386A1 true CA2433386A1 (en) 2002-06-27
CA2433386C CA2433386C (en) 2006-11-21

Family

ID=22971918

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002433386A Expired - Fee Related CA2433386C (en) 2000-12-19 2001-12-19 Compositions and methods involving an essential staphylococcus aureus gene and its encoded protein staau_r9

Country Status (6)

Country Link
US (1) US7326541B2 (en)
EP (1) EP1356293A2 (en)
JP (1) JP2004515251A (en)
AU (2) AU2621202A (en)
CA (1) CA2433386C (en)
WO (1) WO2002050545A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6982153B1 (en) * 1998-12-03 2006-01-03 Targanta Therapeutics, Inc. DNA sequences from staphylococcus aureus bacteriophage 77 that encode anti-microbial polypeptides
US7643055B2 (en) * 2003-04-25 2010-01-05 Aptina Imaging Corporation Motion detecting camera system
CN101686964A (en) 2007-05-22 2010-03-31 威斯康星旧生研究基金会 The anti-bacterial drug targeting of genome maintenance interfaces
US10849992B1 (en) * 2015-04-07 2020-12-01 Alector Llc Methods of screening for sortilin binding antagonists
CN108795803B (en) * 2018-06-07 2021-08-10 上海市水产研究所 Degrading bacterium capable of efficiently degrading malachite green medicament and application thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1207253A (en) 1981-08-17 1986-07-08 Lee D. Simon T4 dna fragment as a stabilizer for proteins expressed by cloned dna
CA1327311C (en) 1987-07-06 1994-03-01 Jesse M. Jaynes Therapeutic antimicrobial polypeptides, their use and methods for preparation
DE3735263C1 (en) * 1987-10-17 1988-08-25 Degussa Process for the preparation of alkali metal salts of L-2-pyrrolidone-5-carboxylic acid
AU699322B2 (en) 1994-04-05 1998-12-03 Exponential Biotherapies, Inc. Antibacterial therapy with genotypically modified bacteriophage
DE69531539T2 (en) 1995-06-16 2004-04-01 Société des Produits Nestlé S.A. Phage resistant streptococcus
US6037123A (en) * 1995-09-15 2000-03-14 Microcide Pharmaceuticals, Inc. Methods of screening for compounds active on Staphylococcus aureus target genes
US6737248B2 (en) 1996-01-05 2004-05-18 Human Genome Sciences, Inc. Staphylococcus aureus polynucleotides and sequences
US5981281A (en) 1996-12-13 1999-11-09 Eli Lilly And Company Method for knockout mutagenesis in Streptococcus pneumoniae
US6043038A (en) * 1998-03-31 2000-03-28 Tularik, Inc. High-throughput screening assays for modulators of primase activity
US6380370B1 (en) * 1997-08-14 2002-04-30 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics
WO1999037661A1 (en) 1998-01-27 1999-07-29 The Rockefeller University Dna replication proteins of gram positive bacteria and their use to screen for chemical inhibitors
WO2001009164A2 (en) 1999-07-29 2001-02-08 The Rockefeller University Dna replication proteins of gram positive bacteria and their use to screen for chemical inhibitors
CA2353563A1 (en) 1998-12-03 2000-06-08 Phagetech Inc. Development of novel anti-microbial agents based on bacteriophage genomics
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus

Also Published As

Publication number Publication date
AU2621202A (en) 2002-07-01
WO2002050545A3 (en) 2003-08-21
EP1356293A2 (en) 2003-10-29
WO2002050545A2 (en) 2002-06-27
AU2002226212B2 (en) 2006-11-16
CA2433386C (en) 2006-11-21
US20030003444A1 (en) 2003-01-02
US7326541B2 (en) 2008-02-05
JP2004515251A (en) 2004-05-27

Similar Documents

Publication Publication Date Title
EP1975172A3 (en) High affinity TGFß nucleic acid ligands and inhibitors
WO2005042716A3 (en) Nucleic acid binding oligonucleotides
CA2395266A1 (en) Use of acid-stable subtilisin proteases in animal feed
EP1741780A3 (en) High affinity oligonucleotide ligands to growth factors
ATE347277T1 (en) COMPOSITION HAVING BACTERIOSTATIC AND BACTERICIDAL PROPERTIES AGAINST BACTERIAL SPORES AND CELLS AND METHOD FOR USE THEREOF FOR TREATING FOOD
CA2270106A1 (en) Nucleic acid purification and process
DE60335543D1 (en) COMPOSITION AND METHOD FOR THE PREPARATION OF NUCLEIC ACIDS FROM SPUTUM
DE602005003507D1 (en) Microorganism isolated from kefir, microorganism culture and products containing this microorganism or microorganism culture
WO2002095055A8 (en) Compositions and methods for use in isolation of nucleic acid molecules
WO1998055110A3 (en) NEW USES FOR COMPOUNDS WHICH REDUCE c-jun GENE EXPRESSION
EP1130091A3 (en) Bacterial RNaseP Proteins and their use in identifying antibacterial compounds
AU4744501A (en) Renilla reniformis fluorescent proteins, nucleic acids encoding the fluorescent proteins and the use thereof in diagnostics, high throughput screening and novelty items
WO2002101073A3 (en) Aryl-benzimidazole compounds having antiinfective activity
EP1273658A4 (en) Novel protein, dna thereof and process for producing the same
WO2003087115A3 (en) Oligomeric compounds having modified phosphate groups
WO2021001646A3 (en) Apolipoprotein b antagonist
CA2433386A1 (en) Compositions and methods involving an essential staphylococcus aureus gene and its encoded protein staau_r9
WO1999001473A3 (en) Anti-bacterial methods and materials
WO2005039494A3 (en) Inhibitors of rnase p proteins as antibacterial compounds
ZA200709370B (en) Euo structural type zeolite containing the cation N,N-dimethyl-N,N-di(3,3-dimethylbutyl)ammonium, and the production method thereof
CA2316113A1 (en) Method for nucleic acid purification using iodine
WO2000014200A3 (en) Essential bacterial genes and their use
WO2002046458A3 (en) Nucleic acids of the human abca5, abca6, abca9, and abca10 genes, vectors containing such nucleic acids and uses thereof
WO2003016908A3 (en) Genes and gene products that confer susceptibility to vancomycin derivative antibiotics and methods and assays for identifying bifunctional glycopeptide antibiotics using same
WO2000003009A3 (en) Genes for the biosynthesis of anticapsin and bacilysine, their isolation and their use

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed